Roxadustat

• GMP format available

Roxadustat is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH), with an IC50 value of 591.4 nM. This compound is primarily used to treat anemia associated with chronic kidney disease (CKD) by stimulating erythropoiesis.

Key features and applications include:

• HIF-PH Inhibition: Inhibits HIF-PH enzymes, leading to increased levels of hypoxia-inducible factors (HIFs) and promoting erythropoietin production.
• Erythropoiesis Stimulation: Increases hemoglobin levels and red blood cell production. Used to treat symptomatic anemia in patients with chronic kidney disease, both dialysis-dependent and non-dialysis-dependent.
• Cancer Research: Investigated for its potential to reduce tumor growth by modulating the tumor microenvironment.

Relevant disease states include:

• Chronic Kidney Disease (CKD): Approved for the treatment of anemia associated with CKD.
• Cancer: Potential applications in reducing tumor growth and improving cancer treatment outcomes.